Hope Funds for Cancer Research

Press Release

Announces Newly Published Research in the Journal *Cancer Research* from Postdoctoral Fellow

For Immediate Release
Media Contact:
Arden Scura
401-847-3286
media@hope-funds.org

Newport, RI - February 3, 2015 - A study was published this week in the journal *Cancer Research*, from one of the Hope Funds for Cancer Research alumni Fellows, Dr. Jurre Kamphorst at the Beatson Institute for Cancer Research. The study shows that scavenging for extracellar proteins is important in nutrient update in pancreas cancer.

"Dr. Kamphorst's, and his collaborators', finding provide important information for cancer metabolism in pancreatic cancer," says Leah Rush Cann, a Hope Funds for Cancer Research Trustee. "We are honored to have supported the work that lead to this finding."

The new research published in the February 1, 2015 issue of the journal *Cancer Research*. To view Dr. Kamphorst's article, Click Here

About Jurre Kamphorst, Ph.D.
Dr. Kamphorst joined the laboratory of Joshua Rabinowitz, M.D., Ph.D. at Princeton University in 2009, as a postdoctoral Fellow, after having received his Ph.D. in analytical chemistry and systems biology from Leiden/Amsterdam Center for Drug Research, Leiden, The Netherlands. In January 2014, Dr. Kamphorst started a faculty appointment at the prestigious Beatson Institute for Cancer Research in Glasgow.

Jurre received a Hope Funds for Cancer Research Fellowship in 2011. His project explored how tumor cells make specific metabolic adaptations to supply the energy and building blocks for their rapid growth. Research in recent years established that one function of oncogenes is to induce these metabolic adaptations. Interfering with cancer cell metabolism is one of the oldest pharmacological approaches to cancer therapy, but is currently limited to the areas of folate and nucleic acid metabolism (e.g., methotrexate and 5-fluorouracil). Recently, Drs. Jurre Kamphorst and Joshua Rabinowitz found, using state-of-the-art mass spectrometry, that the Ras oncogene reprograms fatty acid metabolism. They will now have the opportunity to further investigate the nature and ramifications of this reprogramming, aiming towards finding novel therapeutic approaches that selectively inhibit Ras-driven tumor growth. A particular focus will be on the devastating Ras-driven disease, pancreatic cancer.

About Hope Funds for Cancer Research
The Hope Funds for Cancer Research was formed in 2006 by a group of concerned individuals who have experience in oncology, intellectual property law, investment banking, philanthropy, sociology, and the arts to establish a funding vehicle that would take a rational scientific, medical, and investment approach to granting money to the most interesting and promising

research efforts to address the most difficult-to-treat cancers, including pancreatic, lung, liver, sarcomas, esophageal, brain, gastric, and ovarian cancers. These cancers are insidiously aggressive illnesses that kill most of their victims within months, even with aggressive chemotherapy. The Trustees of the Hope Funds for Cancer Research believe that funding research that could lead to breakthroughs in these areas and increase life expectancy in these types of cancers is at the core of our mission. The Hope Funds for Cancer Research is a 509 (a)(1) charity under 501(c)(3) of the Internal Revenue Service's code. For additional information about the organization, please visit http://www.hope-funds.org or call 401-847-3286.

Hope Funds for Cancer Research: Advancing Innovative Research in Understudied Cancers

To visit our website, click here

02/03/15 - 3

Hope Funds for Cancer Research | 174 Bellevue Avenue, Suite 311 | Newport | RI | 02840